HSIC at a glance
Henry Schein (HSIC, SEC CIK 1000228) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as September 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 27, 2025 (FY2025), Henry Schein (HSIC) reported revenue of $13.2 billion (up 4.0% from FY2024) and net income of $398.0 million. Diluted EPS was $3.27.
- As of September 30, 2026, 37 institutional investment managers tracked by SignalX reported holding Henry Schein (HSIC) shares worth $3.6 billion in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by DANIEL WILLIAM K on May 11, 2026 of 10,000 shares at $69.19 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $13.2B
- +4.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 37 funds
- $3.6B · +1 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 27, 2025
Risk Factors
- CEO Stanley Bergman retiring March 1, 2026 after 37-year tenure; successor Frederick Lowery appointed January 2026 amid intensifying senior management competition
- October 2023 cyberattack disrupted North American and European distribution operations; residual financial impact persisted through 2024 with ongoing remediation costs
- KKR strategic investment of $250M at ~$76.10/share; ownership limit raised to 19.9%, creating potential conflicts via KKR investments in customers, suppliers, or competitors
- False Claims Act exposure: whistleblower relators entitled to up to 30% of government recoveries; penalties include treble damages plus potential Medicare/Medicaid exclusion
- Top 10 Global Distribution suppliers represent ~24% of aggregate purchases; no long-term contracts, creating supply disruption risk for high-margin products
Business Overview
- Global distribution of dental/medical products and services to office-based practitioners, supplemented by specialty products and healthcare technology software
- Global Technology fastest-growing segment at +7.1% driven by cloud-based practice management platform adoption and revenue cycle management solutions; launched Global E-Commerce Platform (henryschein.com)
- Active 2024 restructuring plan (completing 2027) reshaping portfolio via business disposals across all three segments; $105M charges in FY2025 vs $73M in FY2024
- Net sales $13.2B, up 4.0% YoY; share count fell from 124M to 116M as company repurchased $250M via accelerated buyback plus new $750M repurchase authorization
- Total debt surged to $3.1B from $2.5B YoY while operating cash flow declined $136M to $712M; $36M in shareholder advisory/consulting costs flagged as unusual adjustment vs just $2M prior year
Management Discussion & Analysis
- Revenue $13,184M in FY2025, up 4.0% YoY from $12,673M; internal growth 2.6%, acquisitions 0.9%, FX 0.5%
- Gross margin 31.1% vs 31.7% prior year; operating expense ratio 26.2% vs 26.8%; effective tax rate 23.7% vs 24.9%
- Best segment: Global Technology +7.1% sales, gross margin 67.7% vs 67.4%; worst: Global Distribution gross margin 25.0% vs 25.8%
- Operating cash flow $712M vs $848M; investing cash outflow $400M; $250M accelerated share repurchase executed May 2025; $780M remaining buyback capacity; total debt $3,107M vs $2,536M
- Key risks: OBBBA Medicaid cuts and tariffs flagged as likely adverse to utilization and costs; restructuring charges $105M in FY2025 with plan continuing through end of 2027
AI summary of the HSIC 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 26, 2026
Risk Factors
- No material changes from the December 27, 2025 Form 10-K risk factors
- Continued exposure to healthcare distribution competition and pricing pressure
- Continued regulatory and compliance requirements across healthcare markets
- Continued liquidity, credit, and foreign-currency risks from global operations
Management Discussion & Analysis
- Quarterly revenue $3,471M, up 4.0% YoY from $3,339M
- Gross margin 31.8% vs 30.7% YoY, with effective tax rate 23.1% vs 21.3%
- Best segment Global Specialty Products, sales up 6.1% to 11.3% of revenue
- Worst product line Global Value-Added Services, sales down 4.8%
- Nine-month operating cash flow $306M vs $331M, investing cash use $173M vs $253M
- Tariff refund benefit $28M in quarter, additional refunds expected in fourth quarter of 2026
AI summary of the HSIC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Non-GAAP presentation change: acquisition-related remeasurement gains excluded beginning Q4 2026
- Historical 2024, 2025 and nine-month 2026 non-GAAP results recast with reconciliations
Item EX-99.1: Item EX-99.1
- Non-GAAP methodology tightened, excluding acquisition-related fair-value remeasurement gains from Q4 2026 onward
- FY2026 non-GAAP diluted EPS guidance reduced $0.08 to $5.42-$5.48, with no change to underlying business outlook
Item 2.02: Results of Operations and Financial Condition
- Q3 and nine-month fiscal 2026 results released for periods ended September 26, 2026
- Full financial results and management commentary available in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 sales $3.5B, up 4.0%, with U.S. dental merchandise growth 8.6% driven primarily by volume and market-share gains
- Non-GAAP EPS $1.56, up 13.0%; underlying growth 19.1% excluding $0.19 tariff refunds and prior-year $0.23 remeasurement gain
Item EX-99.1: Item EX-99.1
- CFO Emmanuel Caprais starts November 4, 2026, following advisory onboarding October 12
- Incumbent CFO Ronald South transitions to Senior Advisor after 18 years, limiting disruption risk
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CFO transition effective November 4, 2026, with Ronald South continuing through third-quarter earnings completion
- Emmanuel Caprais appointed CFO, bringing prior CFO experience at ITT and structured onboarding beginning October 12, 2026
Item 7.01: Regulation FD Disclosure
- Press release dated October 8, 2026 announces leadership transitions at Henry Schein
- Investor focus: executive succession, continuity of strategy and potential operating impact
AI summaries of HSIC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for HSIC
Don't miss the next HSIC filing
- Alerts as it files. A push when HSIC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut HSIC, by share count.
- Ask anything. An AI agent that reads every HSIC filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Albertini Andrea | D | Sep 8, 2026 | 3,984 | - |
| Albertini Andrea | F | Sep 8, 2026 | 603 | $88.86 |
| DANIEL WILLIAM K | A | Jun 12, 2026 | 2,215 | - |
| BERGMAN STANLEY M | G | May 26, 2026 | 50 | - |
| BERGMAN STANLEY M | G | May 21, 2026 | 50 | - |
| BERGMAN STANLEY M | G | May 19, 2026 | 1,040 | - |
| DANIEL WILLIAM K | Buy | May 11, 2026 | 10,000 | $69.19 |
| Popeck Thomas C | Sell | Mar 19, 2026 | 1,355 | $72.79 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $12.7B | $13.2B |
| Gross Profit | - | $4.0B | $4.1B |
| Operating Income | $615.0M | $621.0M | $653.0M |
| Net Income | $416.0M | $390.0M | $398.0M |
| Gross Margin | - | 31.7% | 31.1% |
| Op. Margin | - | 4.9% | 5.0% |
| Net Margin | - | 3.1% | 3.0% |
| Balance Sheet | |||
| Total Assets | - | $10.2B | $11.2B |
| Equity | - | $3.4B | $3.2B |
| ROE | - | 11.5% | 12.3% |
| Per Share | |||
| EPS | $3.16 | $3.05 | $3.27 |
| Cash Flow | |||
| Operating CF | $500.0M | $848.0M | $712.0M |
Source: XBRL data in Henry Schein (HSIC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate HSIC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 37 | $3.64B |
| Q2 2026 | 36 | $4.28B |
| Q1 2026 | 35 | $3.59B |
| Q4 2025 | 33 | $3.68B |
| Q3 2025 | 36 | $3.79B |
| Q2 2025 | 33 | $3.78B |
| Q1 2025 | 32 | $2.98B |
| Q4 2024 | 29 | $2.48B |
- Millennium Management+613.0K (+15959%)
- Ameriprise Financial+300.2K (+118%)
- Goldman Sachs Group+191.9K (+16%)
- Dimensional Fund Advisors+129.2K (+4%)
- D.E. Shaw & Co+93.9K (+973%)
- Morgan Stanley−977.5K (-47%)
- JPMorgan Chase & Co−772.2K (-18%)
- Invesco Ltd−126.4K (-4%)
- Vanguard Capital Management LLC−94.5K (-1%)
- Vanguard Portfolio Management LLC−64.3K (-2%)
- Renaissance Technologies LLC+160.4K
- Two Sigma Investments+18.3K
- FMR LLC (Fidelity)−7.55M
Source: 13F-HR filings on SEC EDGAR (aggregated from 271 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
HSIC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 10-Q | Nov 3, 2026 | Sep 26, 2026 | Analysis | |
| 8-K | Oct 8, 2026 | - | Analysis | - |
| 8-K | Sep 22, 2026 | - | Analysis | - |
| 4 | Sep 9, 2026 | - | - | - |
| SC 13G | Aug 6, 2026 | - | - | |
| 10-Q | Aug 4, 2026 | Jun 27, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | May 26, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 8-K | May 22, 2026 | - | Analysis | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 10-Q | May 5, 2026 | Mar 28, 2026 | Analysis | |
| SC 13G | Apr 30, 2026 | - | - | |
| 4 | Mar 20, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
Related Health Care companies
- ACH · ACCENDRA HEALTH INC/VA/Wholesale-Medical, Dental & Hospital Equipment & Supplies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
HSIC SEC filings: frequently asked questions
Which institutions hold HSIC stock?
As of September 30, 2026, the largest Henry Schein (HSIC) holders among the 13F filers tracked by SignalX were BlackRock ($592.6 million), Vanguard Capital Management LLC ($525.0 million), State Street Corp ($361.2 million), Vanguard Portfolio Management LLC ($341.7 million), JPMorgan Chase & Co ($303.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was HSIC's revenue in fiscal year 2025?
For the fiscal year ended December 27, 2025 (FY2025), Henry Schein (HSIC) reported revenue of $13.2 billion (up 4.0% from FY2024) and net income of $398.0 million. Diluted EPS was $3.27. The figures come from the XBRL data in the 10-K.
What are the main risks in HSIC's latest 10-K?
In the 10-K filed February 24, 2026, Henry Schein (HSIC) flagged: CEO Stanley Bergman retiring March 1, 2026 after 37-year tenure; successor Frederick Lowery appointed January 2026 amid intensifying senior management competition. October 2023 cyberattack disrupted North American and European distribution operations; residual financial impact persisted through 2024 with ongoing remediation costs. (AI summary of the Risk Factors section.)
What did HSIC report in its latest 8-K?
Henry Schein (HSIC) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure). Non-GAAP presentation change: acquisition-related remeasurement gains excluded beginning Q4 2026.
What are the latest HSIC SEC filings?
Henry Schein (HSIC) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on September 9, 2026.
What is HSIC's SEC CIK number?
Henry Schein (HSIC)'s SEC Central Index Key (CIK) is 1000228. EDGAR lists every HSIC filing under that number.
Ask anything about HSIC
The research agent reads HSIC's filings, financials, insider trades and 13F holders, then answers with sources.